Research and development expense was $15.5 million for the third quarter of 2024, as compared to $7.6 million for the prior ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and ...

Schizophrenia significantly shortens life expectancy by an estimated 15 years with excess mortality arising from multiple ...

Vertex has reached a key moment because the U.S. Food and Drug Administration (FDA) is reviewing its candidate, suzetrigine, ...

Vertex also reported a steady increase in its R&D and SG&A expenses, reflecting its aggressive investment in pipeline ...

Vertex Pharmaceuticals Inc. ( (VRTX) ) has released its Q3 earnings. Here is a breakdown of the information Vertex Pharmaceuticals Inc.

Vertex Pharmaceuticals Inc. (VRTX) has disclosed a new risk, in the Innovation / R&D category. Vertex Pharmaceuticals Inc. faces ...

Sigma Planning Corp trimmed its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 8.7% during the third quarter, according to its most recent disclosure with the ...

These are the 300 companies whose success goes beyond profits to include employee and customer sentiment, cybersecurity, ...

Investors with a lot of money to spend have taken a bullish stance on Vertex Pharmaceuticals VRTX. And retail traders should ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its target price raised by research analysts at Scotiabank from ...